Amylyx Pharmaceuticals Inc (AMLX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMLX
Amylyx Pharmaceuticals Inc
$23.35
-1.18%
HEALTHCARE · Cap: $2.26B
TEVA
Teva Pharma Industries Ltd ADR
$36.48
+0.71%
HEALTHCARE · Cap: $40.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates -2603859% more annual revenue ($17.32B vs $-665,000). TEVA leads profitability with a 4.1% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 49/100 (D+).
AMLX
Avoid33
out of 100
Grade: F
TEVA
Hold49
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Trading at 9.5x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : AMLX
The primary concerns for AMLX are Price/Book, EPS Growth, Profit Margin.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 58.4x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.86 — expect wider price swings.
TEVA is growing revenue faster at -0.8% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (49/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?